Testing Performance and Usability of Q300 Device

Not Applicable

Completed

• Conditions: Healthy
• Interventions: Diagnostic Test: QISI device

• Registration Number: NCT04901572
• Lead Sponsor: QART Medical

Brief Summary

A data collection clinical study performed on live human spermatozoa samples. Spermatozoa are imaged by QART Q300TM microscopy system. For the feasibility 1st phase of the study, up to 75 donors are expected to participate. Study group will include sperm samples donated by the clinic's patients (recruited by the investigators from the clinic's patient database) and/or by healthy volunteers (responding to advertisement).

Detailed Description

Cells will be individually selected by the system, and will be representative of the cell population to be selected in ICSI procedures. Each selected cell will be imaged by the QART system and independently and blindly reviewed by an Embryologist(s) team. According to these, each cell will be scored as 'Normal' or 'Abnormal' per WHO guidelines. Sperm cells that were successfully imaged with Q300, will be individually stained. Each stained cell will be imaged by BFM and the non-labeled image will be digitally stored (BFM-NL). The BFM-NL Image will be independently and blindly reviewed by an Embryologist team and scored as 'Normal' or 'Abnormal' per their best discretion.

The database generated in this study will be used for (i) testing the performance accuracy of the Q300 system for sperm cell dimensional measurements, (ii) providing feedback to the study sponsor (QART Medical Ltd.) regarding the usability of the Q300 system, (iii) further improving and testing the accuracy of the QART Feature Extraction algorithms and (v) assisting in determining the inclusion/exclusion criteria for subsequent clinical stages. In final validation stages, the conventional staining results will be statistically compared with the Q300 feature extraction results for each individual sperm cell. During the study, ICSI laboratory personnel (at least 10) will evaluate the suggested use scenarios of the device; device components and user interface, the simplicity of use, duration of use, level of expertise required from the Q300 operator, clarity in the use sequences, and perceived added complexity compared with contemporary ICSI routine.

Study Timeline

• Study First Submitted: 2021-05-19
• Study First Submitted QC: 2021-05-20
• Study First Posted: 2021-05-25
• Study Start: 2021-09-01
• Primary Completion: 2023-04-04
• Study Completion: 2023-04-04
• Status Verified: 2023-06
• Last Update Submitted: 2023-06-27
• Last Update Posted: 2023-06-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 75

Inclusion Criteria

1. Healthy volunteers
2. Patients recruited from the hospital's andrology/IVF departments
3. Male, Age >18
4. Patient signed on informed consent

Exclusion Criteria

1. Severe Oligozoospermia (less than 1 million sperm cells after preparation).
2. Documented presence of infectious disease transmitted in sperm fluids (e.g. HIV, HBV, HCV, Covid-19)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
QART Imaging	QISI device	Cells will be individually selected with the system's micromanipulator under bright-field imaging. The cells will be representative of the cell population to be selected in ICSI procedures, covering the entire range of human sperm cell dimensions. Each selected cell will be simultaneously imaged by the QART system in two modalities: 1. Standard brightfield. 2. QART's imaging methodology.

Primary Outcome Measures

Name	Time	Method
Demonstrate agreement between the Q300 results to the reference method	1 Day	Demonstrate agreement between Q300 results, and Chemically stained image. the Q300 results will be provided automatically for each individual cell that will be images by the system, the reference method measurements will be provided by core lab embryologist and using a marking tool application.
evaluate the repeatability of the Q300 device results and compare it to the reference method repeatability.	1 Day	repeatability of bot the device measurements and the reference method will be evaluated and compared.
agreement of individual sperm cell's classification will be compared between the Q300 device and the reference method.	1 Day	agreement of individual sperm cell's classification (comply with WHO2021 criteria or non comply) will be compared between the Q300 device automatic results and the reference method results.

Secondary Outcome Measures

Name	Time	Method
Usability of the Q300 device will be evaluated	1 Day	Usability of the Q300 device will be evaluated using usability questionnaire.

Trial Locations

Locations (4)

Shaare Zedek Medical Center; 🇮🇱 Jerusalem, Israel

Barzilai Medical Center; 🇮🇱 Ashkelon, Israel

Meir Medical Center; 🇮🇱 Kfar Saba, Israel

Wolfson Medical Center; 🇮🇱 H̱olon, Israel